LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

Revvity Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

103.28 0.61

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

102.77

Max

104.47

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-8.6M

47M

Pardavimai

-21M

699M

P/E

Sektoriaus vid.

52.799

80.03

Pelnas, tenkantis vienai akcijai

1.18

Dividendų pajamingumas

0.27

Pelno marža

6.675

Darbuotojai

11,000

EBITDA

-14M

181M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+8.46% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.27%

2.29%

Kita Ex Dividend data

2026-01-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

612M

12B

Ankstesnė atidarymo kaina

102.67

Ankstesnė uždarymo kaina

103.28

Revvity Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-03 23:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

2025-12-03 23:14; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5 Million

2025-12-03 22:01; UTC

Pagrindinės rinkos jėgos

Costco Wholesale Reports Higher Monthly Sales

2025-12-03 21:38; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

2025-12-03 23:59; UTC

Rinkos pokalbiai

Australian Coal Prices Seen Having Recovered Well -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

2025-12-03 23:13; UTC

Rinkos pokalbiai

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

2025-12-03 23:10; UTC

Uždarbis

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

2025-12-03 23:08; UTC

Rinkos pokalbiai

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

2025-12-03 23:06; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

2025-12-03 22:59; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5M

2025-12-03 22:45; UTC

Rinkos pokalbiai

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

2025-12-03 22:20; UTC

Uždarbis

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

2025-12-03 22:19; UTC

Uždarbis

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

2025-12-03 22:17; UTC

Uždarbis

Salesforce Working to Add Voice to Agentforce, CEO Says

2025-12-03 22:16; UTC

Uždarbis

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

2025-12-03 22:15; UTC

Uždarbis

Salesforce CEO: Agentforce ARR Was $540M in 3Q

2025-12-03 22:10; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

2025-12-03 22:09; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

2025-12-03 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-03 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-03 21:49; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:23; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

2025-12-03 21:19; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:06; UTC

Uždarbis

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

2025-12-03 21:04; UTC

Uždarbis

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

2025-12-03 21:04; UTC

Uždarbis

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

2025-12-03 21:03; UTC

Uždarbis

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Akcijų palyginimas

Kainos pokytis

Revvity Inc Prognozė

Kainos tikslas

By TipRanks

8.46% į viršų

12 mėnesių prognozė

Vidutinis 111.1 USD  8.46%

Aukščiausias 125 USD

Žemiausias 100 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Revvity Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

8

Pirkti

3

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat